Equities

Sonnet Biotherapeutics Holdings Inc

SONN:NAQ

Sonnet Biotherapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.05
  • Today's Change-0.25 / -7.58%
  • Shares traded144.61k
  • 1 Year change-67.69%
  • Beta0.4878
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments2.273.0528
Total Receivables, Net0.79----
Total Inventory------
Prepaid expenses1.682.361.19
Other current assets, total------
Total current assets4.745.4129
Property, plant & equipment, net0.230.300.18
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.41--0
Total assets5.435.8329
LIABILITIES
Accounts payable2.204.753.78
Accrued expenses3.303.252.40
Notes payable/short-term debt00.000.00
Current portion long-term debt/capital leases------
Other current liabilities, total0.020.170.52
Total current liabilities5.528.166.70
Total long term debt000
Total debt00.000.00
Deferred income tax------
Minority interest------
Other liabilities, total0.130.200.03
Total liabilities5.668.376.73
SHAREHOLDERS EQUITY
Common stock0.000.000.01
Additional paid-in capital1108984
Retained earnings (accumulated deficit)(110)(91)(62)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(0.23)(2.54)22
Total liabilities & shareholders' equity5.435.8329
Total common shares outstanding0.220.030.02
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.